Search

Displaying results 1901 - 1910 of 3733 in total
  1. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  2. Drug

    Oliceridine

    go.drugbank.com/drugs/DB14881
    ApprovedInvestigational

    [A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor … [A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  3. Drug

    RO7284755

    go.drugbank.com/drugs/DB17527
    Investigational

    RO7284755 is an investigational cancer drug: it is a PD-1-targeted IL-2 variant antibody fusion protein.

  4. Drug

    Zolazepam

    go.drugbank.com/drugs/DB11555
    ExperimentalVet approved

    It is around four times the potency of diazepam but it is both water-soluble and un-ionized at physiological pH meaning that its onset is very fast.

  5. Drug

    Zinc chloride

    go.drugbank.com/drugs/DB14533
    Approved

    Zinc chloride is a solution of ions indicated for use in total parenteral nutrition to maintain zinc levels and prevent deficiency syndromes. Zinc chloride was granted FDA approval before 26 June 1986.

    Mixtures: PM Toothache Relief, Orajel 4X Medicated PM For Toothache and Gum
  6. Drug

    Witch hazel

    go.drugbank.com/drugs/DB11111
    ApprovedInvestigationalNutraceutical

    Mixtures: Preparation H-PE Gel, PREPARATION H PE COOLING GELProducts: Centellaca Reset, Hydra C3 Triple Reset
  7. Drug

    Avacopan

    go.drugbank.com/drugs/DB15011
    ApprovedInvestigational

    fragment C5a and its cognate C5aR receptor in AAV. … [A240249, A240254] Despite complex pathophysiology, studies over the past ~2 decades have identified a key role for the alternative complement pathway and, in particular, the interaction between the anaphylatoxin

    Categories: Complement 5a Receptor Antagonist, P-glycoprotein substrates
  8. Drug

    Varlitinib

    go.drugbank.com/drugs/DB05944
    Investigational

    Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients.

  9. Drug

    Zanubrutinib

    go.drugbank.com/drugs/DB15035
    ApprovedInvestigational

    Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell n...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  10. Drug

    Ancremonam

    go.drugbank.com/drugs/DB19710
    Investigational

    Ancremonam is under investigation in clinical trial NCT03377426 (LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)).